Scintigraphic tracking of 99mTechnetium-labelled equine peripheral blood-derived mesenchymal stem cells after intravenous, intramuscular, and subcutaneous injection in healthy dogs
© 2021. The Author(s)..
BACKGROUND: Mesenchymal stem cell treatments in dogs have been investigated as a potential innovative alternative to current conventional therapies for a variety of conditions. So far, the precise mode of action of the MSCs has yet to be determined. The aim of this study was to gain more insights into the pharmacokinetics of MSCs by evaluating their biodistribution in healthy dogs after different injection routes.
METHODS: Three different studies were performed in healthy dogs to evaluate the biodistribution pattern of radiolabelled equine peripheral blood-derived mesenchymal stem cells following intravenous, intramuscular and subcutaneous administration in comparison with free 99mTechnetium. The labelling of the equine peripheral blood-derived mesenchymal stem cells was performed using stannous chloride as a reducing agent. Whole-body scans were obtained using a gamma camera during a 24-h follow-up.
RESULTS: The labelling efficiency ranged between 59.58 and 83.82%. Free 99mTechnetium accumulation was predominantly observed in the stomach, thyroid, bladder and salivary glands, while following intravenous injection, the 99mTechnetium-labelled equine peripheral blood-derived mesenchymal stem cells majorly accumulated in the liver throughout the follow-up period. After intramuscular and subcutaneous injection, the injected dose percentage remained very high at the injection site.
CONCLUSIONS: A distinct difference was noted in the biodistribution pattern of the radiolabelled equine peripheral blood-derived mesenchymal stem cells compared to free 99mTechnetium indicating equine peripheral blood-derived mesenchymal stem cells have a specific pharmacokinetic pattern after systemic administration in healthy dogs. Furthermore, the biodistribution pattern of the used xenogeneic equine peripheral blood-derived mesenchymal stem cells appeared to be different from previously reported experiments using different sources of mesenchymal stem cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Stem cell research & therapy - 12(2021), 1 vom: 13. Juli, Seite 393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beerts, Charlotte [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7440-26-8 |
|---|
| Anmerkungen: |
Date Completed 06.08.2021 Date Revised 06.08.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13287-021-02457-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328025151 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328025151 | ||
| 003 | DE-627 | ||
| 005 | 20231225202055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13287-021-02457-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM328025151 | ||
| 035 | |a (NLM)34256833 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beerts, Charlotte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Scintigraphic tracking of 99mTechnetium-labelled equine peripheral blood-derived mesenchymal stem cells after intravenous, intramuscular, and subcutaneous injection in healthy dogs |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.08.2021 | ||
| 500 | |a Date Revised 06.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Mesenchymal stem cell treatments in dogs have been investigated as a potential innovative alternative to current conventional therapies for a variety of conditions. So far, the precise mode of action of the MSCs has yet to be determined. The aim of this study was to gain more insights into the pharmacokinetics of MSCs by evaluating their biodistribution in healthy dogs after different injection routes | ||
| 520 | |a METHODS: Three different studies were performed in healthy dogs to evaluate the biodistribution pattern of radiolabelled equine peripheral blood-derived mesenchymal stem cells following intravenous, intramuscular and subcutaneous administration in comparison with free 99mTechnetium. The labelling of the equine peripheral blood-derived mesenchymal stem cells was performed using stannous chloride as a reducing agent. Whole-body scans were obtained using a gamma camera during a 24-h follow-up | ||
| 520 | |a RESULTS: The labelling efficiency ranged between 59.58 and 83.82%. Free 99mTechnetium accumulation was predominantly observed in the stomach, thyroid, bladder and salivary glands, while following intravenous injection, the 99mTechnetium-labelled equine peripheral blood-derived mesenchymal stem cells majorly accumulated in the liver throughout the follow-up period. After intramuscular and subcutaneous injection, the injected dose percentage remained very high at the injection site | ||
| 520 | |a CONCLUSIONS: A distinct difference was noted in the biodistribution pattern of the radiolabelled equine peripheral blood-derived mesenchymal stem cells compared to free 99mTechnetium indicating equine peripheral blood-derived mesenchymal stem cells have a specific pharmacokinetic pattern after systemic administration in healthy dogs. Furthermore, the biodistribution pattern of the used xenogeneic equine peripheral blood-derived mesenchymal stem cells appeared to be different from previously reported experiments using different sources of mesenchymal stem cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biodistribution | |
| 650 | 4 | |a Canine | |
| 650 | 4 | |a Equine peripheral blood | |
| 650 | 4 | |a Mesenchymal stem cells | |
| 650 | 4 | |a Scintigraphy | |
| 650 | 4 | |a Xenogeneic | |
| 650 | 7 | |a Technetium |2 NLM | |
| 650 | 7 | |a 7440-26-8 |2 NLM | |
| 700 | 1 | |a Brondeel, Carlien |e verfasserin |4 aut | |
| 700 | 1 | |a Pauwelyn, Glenn |e verfasserin |4 aut | |
| 700 | 1 | |a Depuydt, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Tack, Liesa |e verfasserin |4 aut | |
| 700 | 1 | |a Duchateau, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yangfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Jimmy H |e verfasserin |4 aut | |
| 700 | 1 | |a Peremans, Kathelijne |e verfasserin |4 aut | |
| 700 | 1 | |a Spaas, Jan H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stem cell research & therapy |d 2010 |g 12(2021), 1 vom: 13. Juli, Seite 393 |w (DE-627)NLM198410786 |x 1757-6512 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:13 |g month:07 |g pages:393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13287-021-02457-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |b 13 |c 07 |h 393 | ||